Durable Remissions in CLL With Fixed-Duration Triplet at 4 Years
Four-year follow-up data from a phase II study evaluating obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL) were presented at the American Society of Clinical Oncology annual meeting. In this exclusive MedPage Today video, Kerry Rogers, MD, of the Ohio State University Comprehensive Cancer Center in Columbus, discusses the […]